Answers are grounded in this paper and cite their sources.
Demonstrates differing immune responses in relapsing and progressive multiple sclerosis, indicating distinct treatment approaches.
Our findings support divergent immunological mechanisms in RMS and PPMS, with a stronger cytokine-driven pathology and more pronounced immunomodulatory effects of ocrelizumab on the cytokine profile in patients with RMS.
No takes yet. Share an insight, caveat, or question.
Körner et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: